PMID- 36263703
OWN - NLM
STAT- MEDLINE
DCOM- 20221116
LR  - 20221116
IS  - 2042-650X (Electronic)
IS  - 2042-6496 (Linking)
VI  - 13
IP  - 22
DP  - 2022 Nov 14
TI  - Propolis supplementation in obese patients with non-alcoholic fatty liver 
      disease: effects on glucose homeostasis, lipid profile, liver function, 
      anthropometric indices and meta-inflammation.
PG  - 11568-11578
LID - 10.1039/d2fo01280d [doi]
AB  - This study assessed the effects of propolis supplementation on glucose 
      homeostasis, lipid profile, liver function, anthropometric indices and 
      meta-inflammation in patients with non-alcoholic fatty liver disease (NAFLD). In 
      this double-blind placebo-controlled randomized clinical trial, 44 patients with 
      NAFLD confirmed by ultrasonography findings were randomly allocated into either 
      the "propolis" (n = 23) or "placebo" (n = 21) group along with a 
      calorie-restricted diet (-500 kcal d(-1)) for 8 weeks. Fasting serum levels of 
      metabolic factors, liver enzymes, and inflammatory factors, as well as 
      anthropometric indices, dietary intake and appetite status were assessed pre-and 
      post-intervention. The liver fibrosis score, homeostasis model assessment of 
      insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index 
      (QUICKI) were also calculated. The weight, body mass index (BMI), waist and hip 
      circumferences, and waist to height ratio significantly decreased in both groups 
      (p < 0.001), while the waist to hip ratio (p = 0.006) and serum level of total 
      cholesterol (p = 0.038) decreased only in the propolis arm. However, no 
      significant changes in anthropometric measurements and lipid profile were found 
      between the groups at the end of the intervention. Fasting blood sugar (p = 
      0.037), the serum insulin level (p = 0.040), HOMA-IR (p = 007), desire to eat 
      sweet foods (p = 0.005) and the NAFLD fibrosis score (p = 0.013) decreased 
      significantly in the propolis group compared to the placebo group, 
      post-intervention after adjusting for baseline values and potential confounders. 
      However, QUICKI showed a significant increase (p = 0.015) in the propolis arm 
      compared to the placebo at the study endpoint. Although there were significant 
      reductions in the serum levels of inflammatory factors including tumor necrosis 
      factor-alpha (TNF-alpha), toll-like receptor-4 (TLR-4) and monocyte chemoattractant 
      protein-1 (MCP-1), as well as liver enzymes and severity of fatty liver, 
      between-group differences were not statistically significant after adjusting for 
      the potential confounding factors. The estimated number needed to treat (NNT) due 
      to 8-week propolis supplementation (510 mg per day) for at least 1-point 
      improvement in NAFLD severity was found to be approximately 3. In conclusion, 
      propolis supplementation along with a calorie-restricted diet for 8 weeks could 
      significantly improve the glucose homeostasis, hepatic fibrosis score and liver 
      function in patients with NAFLD. Further clinical trials are encouraged to study 
      the effects of propolis supplementation in patients with long-term NAFLD.
FAU - Nikbaf-Shandiz, Mahlagha
AU  - Nikbaf-Shandiz M
AD  - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Tutunchi, Helda
AU  - Tutunchi H
AUID- ORCID: 0000-0002-4795-1757
AD  - Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Khoshbaten, Manuchehr
AU  - Khoshbaten M
AD  - Department of Internal Medicine, Faculty of Medicine, Tabriz University of 
      Medical Sciences, Tabriz, Iran.
FAU - Nazari Bonab, Hamideh
AU  - Nazari Bonab H
AD  - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Ebrahimi-Mameghani, Mehrangiz
AU  - Ebrahimi-Mameghani M
AUID- ORCID: 0000-0002-0311-1289
AD  - Nutrition Research Center, Department of Biochemistry and Diet Therapy, Faculty 
      of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, 
      Iran. ebrahimimamagani@tbzmed.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20221114
PL  - England
TA  - Food Funct
JT  - Food & function
JID - 101549033
RN  - 9009-62-5 (Propolis)
RN  - 0 (Lipids)
RN  - IY9XDZ35W2 (Glucose)
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Humans
MH  - *Non-alcoholic Fatty Liver Disease/metabolism
MH  - *Propolis
MH  - Obesity/drug therapy
MH  - Inflammation/drug therapy
MH  - Homeostasis
MH  - Dietary Supplements/adverse effects
MH  - Lipids
MH  - Glucose
MH  - Double-Blind Method
MH  - *Insulin Resistance
MH  - Blood Glucose/metabolism
EDAT- 2022/10/21 06:00
MHDA- 2022/11/18 06:00
CRDT- 2022/10/20 04:13
PHST- 2022/10/21 06:00 [pubmed]
PHST- 2022/11/18 06:00 [medline]
PHST- 2022/10/20 04:13 [entrez]
AID - 10.1039/d2fo01280d [doi]
PST - epublish
SO  - Food Funct. 2022 Nov 14;13(22):11568-11578. doi: 10.1039/d2fo01280d.